The drug API Innovation Center has reached a milestone in the development of technology essential to accelerating the U.S. production of lomustine, a critical cancer medication, and will collaborate with St. Louis-based Apertus Pharmaceuticals to expand its manufacturing in Missouri. In the fight against glioblastoma—the most common and aggressive form of malignant brain cancer—doctors and patients turn to lomustine, a leading chemotherapy treatment relying on active pharmaceutical ingredient...